Title: The Effect of Probiotic Supplementation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Fibrosis Score in Patients Attending a Tertiary Hospital Clinic in Cairo, Egypt
Version: 4 Date: 02 Jul 2024
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
The strength of this study is the evaluation of the NAFLD fibrosis score after probiotic
supplementation. However, many points should be clarified:
1. Introduction: "currently, no drug is registered for the treatment of NASH.". However,
FDA approved the use of Resmetirom. Please include this in this section doi: 10.1056/
NEJMoa2309000;
2. It should be clarified how the sample size calculation was done in addition to the software
used;
3. Please revise the abbreviations in the manuscript;
4. What are the limitations of this study?
Title: The Effect of Probiotic Supplementation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Fibrosis Score in Patients Attending a Tertiary Hospital Clinic in Cairo, Egypt
Version: 4 Date: 02 Jul 2024
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
The strength of this study is the evaluation of the NAFLD fibrosis score after probiotic
supplementation. However, many points should be clarified:
1. Introduction: "currently, no drug is registered for the treatment of NASH.". However,
FDA approved the use of Resmetirom. Please include this in this section doi: 10.1056/
NEJMoa2309000;
2. It should be clarified how the sample size calculation was done in addition to the software
used;
3. Please revise the abbreviations in the manuscript;
4. What are the limitations of this study?
Please review this paper.
user
Title: The Effect of Probiotic Supplementation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Fibrosis Score in Patients Attending a Tertiary Hospital Clinic in Cairo, Egypt
Version: 4 Date: 02 Jul 2024
Reviewer:  Giuseppe Guido Maria Scarlata
Reviewer's report:
The strength of this study is the evaluation of the NAFLD fibrosis score after probiotic
supplementation. However, many points should be clarified:
1. Introduction: "currently, no drug is registered for the treatment of NASH.". However,
FDA approved the use of Resmetirom. Please include this in this section doi: 10.1056/
NEJMoa2309000;
2. It should be clarified how the sample size calculation was done in addition to the software
used;
3. Please revise the abbreviations in the manuscript;
4. What are the limitations of this study?
assistant